kvpharm_8k-080412.htm

0001437749-12-007870.txt : 20120808 0001437749-12-007870.hdr.sgml : 20120808 20120807180122 ACCESSION NUMBER: 0001437749-12-007870 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 5 CONFORMED PERIOD OF REPORT: 20120804 ITEM INFORMATION: Bankruptcy or Receivership ITEM INFORMATION: Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement ITEM INFORMATION: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20120808 DATE AS OF CHANGE: 20120807 FILER: COMPANY DATA: COMPANY CONFORMED NAME: KV PHARMACEUTICAL CO /DE/ CENTRAL INDEX KEY: 0000057055 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 430618919 STATE OF INCORPORATION: DE FISCAL YEAR END: 0331 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-09601 FILM NUMBER: 121014563 BUSINESS ADDRESS: STREET 1: 2280 SCHUETZ ROAD CITY: ST. LOUIS STATE: MO ZIP: 63146 BUSINESS PHONE: 3146456600 MAIL ADDRESS: STREET 1: 2280 SCHUETZ ROAD CITY: ST. LOUIS STATE: MO ZIP: 63146 8-K 1 kvpharm_8k-080412.htm FORM 8-K kvpharm_8k-080412.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

____________________

FORM 8-K

____________________

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (date of earliest event reported): August 4, 2012

K-V PHARMACEUTICAL COMPANY

(Exact name of registrant as specified in its charter)

____________________

Delaware	1-9601	43-0618919
(State or other jurisdiction of incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)

2280 Schuetz Road
St. Louis, MO		63146
(Address of principal executive offices)		(Zip Code)

(314) 645-6600

(Registrant's telephone number, including area code)

____________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o	Written communications pursuant to Rule 425 under the Securities Act.

o	Soliciting material pursuant to Rule 14a-12 under the Exchange Act.

o	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

o	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

Item 1.03

Bankruptcy or Receivership

On August 4, 2012, K-V Pharmaceutical Company (the “Company”) and certain of its wholly-owned domestic subsidiaries listed on Exhibit 99.1, which is incorporated by reference herein, (the “Filing Subsidiaries” and together with the Company, the “Debtors”) filed voluntary petitions for reorganization (the “Chapter 11 Cases”) under Chapter 11 of Title 11 of the United States Code (the “Bankruptcy Code”) in the United States Bankruptcy Court for the Southern District of New York (the “Bankruptcy Court”). The Chapter 11 Cases have been assigned to the Honorable Allan L. Gropper and are being jointly administered under the caption “In re K-V Discovery Solutions, Inc., et al.,” Case No. 12-13346 (ALG). The Debtors will continue to operate their businesses as “debtors-in-possession” under the jurisdiction of the Bankruptcy Court and in accordance with the applicable provisions of the Bankruptcy Code and the orders of the Bankruptcy Court.

On August 4, 2012, the Company announced, through a press release, the Debtors’ filing of the Chapter 11 Cases. A copy of the press release is attached hereto as Exhibit 99.2.

Item 2.04

Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement

The filing of the Chapter 11 Cases described in Item 1.03 above constitutes an event of default and triggers the automatic and immediate acceleration of debt outstanding under the terms of certain instruments and agreements relating to financial obligations of the Debtors (the “Accelerated Financial Obligations”). The material Accelerated Financial Obligations include:

the $225.0 million aggregate principal amount of 12% Senior Secured Notes due 2015; and

the $200.0 million aggregate principal amount of 2.5% Contingent Convertible Subordinated Notes due 2033.

The Debtors believe that any efforts to enforce such Accelerated Financial Obligations against the Debtors are stayed under the Bankruptcy Code as a result of the filing of the Chapter 11 Cases in the Bankruptcy Court.

Item 3.01

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

On August 6, 2012, the New York Stock Exchange (the “NYSE”) announced that it had determined to commence proceedings to delist the Company’s Class A Common Stock and Class B Common Stock (together, the “Common Stock”). The NYSE also announced that trading in the Common Stock on the NYSE would be immediately suspended. The NYSE stated that its decision to delist the Company was reached as a result of the bankruptcy filing by the Company and the other Debtors of the Chapter 11 Cases in the Bankruptcy Court as described in Item 1.03 above. The filing of the Chapter 11 Cases by the Debtors is sufficient grounds for the commencement of delisting procedures by the NYSE under Section 802.01D of the NYSE Listed Company Manual.

The Company has informed the NYSE that it does not intend to appeal the NYSE’s decision. As a result, it is expected that the Common Stock will be delisted after the completion of the NYSE’s application to the Securities and Exchange Commission to delist the Common Stock.

Item 7.01

Regulation FD Disclosure.

On August 7, 2012, the Company issued a press release regarding its suspension from trading on the NYSE and the trading of its Class A and Class B common stock on the over the counter market. A copy of the press release is attached hereto as Exhibit 99.3. The information in the Item 7.01, including the exhibit, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section.

Item 9.01

Financial Statements and Exhibits.

(d)

The following exhibits are furnished as part of this report:

	Exhibit Number		Description

	99.1		List of Filing Subsidiaries

	99.2		Press Release dated August 4, 2012, issuedby K-V Pharmaceutical Company.

	99.3		Press Release dated August 7, 2012, issuedby K-V Pharmaceutical Company

The Company will post this Form 8-K on its Internet website at www.kvpharmaceutical.com. References to the Company’s website address and other websites are included in this Form 8-K and the press releases only as inactive textual references and the Company does not intend them to be active links to those websites. Information contained on those websites do not constitute part of this Form 8-K or the press release.

* * *

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: August 7, 2012

	K-V PHARMACEUTICAL COMPANY

	By:	/s/ Patrick J. Christmas
		Patrick J. Christmas Vice President, General Counsel and Secretary

EX-99.1 2 ex99-1.htm EXHIBIT 99.1 ex99-1.htm

Exhibit 99.1

List of the Filing Subsidiaries

DrugTech Corporation

FP1096, Inc.

K-V Discovery Solutions, Inc.

K-V Generic Pharmaceuticals, Inc.

K-V Solutions USA, Inc.

Ther-Rx Corporation

Zeratech Technologies USA, Inc.

EX-99.2 3 ex99-2.htm EXHIBIT 99.2 ex99-2.htm

Exhibit 99.2

Contact Information:

Brainerd Communicators, Inc.

Tony Herrling

212-739-6738

herrling@braincomm.com

Brad Edwards

212-739-6724

edwards@braincomm.com

K-V Pharmaceutical Company Files Voluntary Petitions for Reorganization to Restructure Financial Obligations

Company continues to operate its businesses and serve the needs of healthcare providers and patients

St. Louis, MO, August 4, 2012 – K-V Pharmaceutical Company (NYSE: KVa/ KVb) (“K-V” or “the Company”) and certain of its domestic subsidiaries today filed voluntary Chapter 11 petitions under the U.S. Bankruptcy Code in the United States Bankruptcy Court for the Southern District of New York, seeking the protection of Chapter 11 while it seeks to restructure its financial obligations.

The Company intends to continue to operate during the reorganization, subject to the supervision and orders of the Bankruptcy Court and in accordance with applicable provisions of the Bankruptcy Code, paying employees and vendors in the normal course of business for goods and services provided postfiling, and providing its women’s health care products without interruption to meet the needs of the healthcare providers and patients it serves.

“K-V came to this decision to seek the protection of Chapter 11 reluctantly, after exploring a full range of options,” said Greg Divis, President and CEO of K-V Pharmaceutical. “Prior to filing our petitions, our Company has worked tirelessly to address significant financial obligations, stemming from legacy regulatory and legal issues. The Company has been unable to realize the full value of its most important product, Makena® (hydroxyprogesterone caproate injection), because of a lack of enforcement of the orphan drug marketing exclusivity granted to K-V for Makena® by the Food and Drug Administration (FDA). The lack of enforcement has also led certain state Medicaid agencies to impose barriers to access to Makena® on low-income pregnant women at high risk for recurrent preterm birth, despite those states’ legal obligation to cover FDA-approved drugs. The Chapter 11 filing is intended to provide K-V with the time needed to continue to conduct our business and restructure our financial obligations as we continue our efforts to ensure that all clinically-indicated patients have access to Makena®. It is our intention to emerge from this restructuring as a stable and competitive company, able to continue to provide quality products to support the health of women across the stages of their lives.”

Further Background to K-V’s Chapter 11 Petition

The Company reported in its filing papers that restrictions on reimbursement imposed by a number of State Medicaid agencies, as well as significant restrictions on manufacturing and marketing of other K-V products imposed by a previous FDA Consent Decree agreed to by the Company in March 2009 have also had a major negative impact on its revenues and ability to meet short and long-term obligations.

These obligations include a milestone payment under the terms of the Company’s agreement with Hologic Inc. pursuant to which the Company purchased all rights to Makena®. The Company was unsuccessful prior to the filing in obtaining a renegotiation of the milestone payments owed to Hologic on terms that were acceptable to the Company. As a result, the Company was forced to file these Chapter 11 cases. The Company has enough cash on hand to operate its business in the near term and intends to seek new financing and use of cash collateral to provide additional time to enable the Company to continue operations, as it takes additional steps to restructure its financial obligations.

The Company has also been actively managing a number of legacy liabilities, most notably the impact of the consent decree formed with the FDA in March 2009, the penalties associated with its settlement with the U.S. Department of Justice in December 2011 related to the Company’s former ETHEX generic pharmaceutical subsidiary, and other ongoing securities and other litigation matters.

Subject to the approval of the Bankruptcy Court, K-V has retained the services of Willkie Farr & Gallagher LLP as bankruptcy counsel, Williams & Connolly LLP as special litigation counsel, and SNR Denton as special litigation counsel. In addition, K-V has retained Jefferies & Co., Inc. as financial advisor and investment banker.

About K-V Pharmaceutical Company

K-V Pharmaceutical Company is a specialty branded pharmaceutical company with a primary focus in the area of women’s healthcare. As such, we are committed to advancing the health of women across all the stages of their lives.

For further information about K-V Pharmaceutical Company, please visit the Company’s corporate Website at www.kvpharmaceutical.com.

Cautionary Note Regarding Forward-looking Statements

This release contains various forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995 (the “PSLRA”) and which may be based on or include assumptions concerning our operations, future results and prospects. Such statements may be identified by the use of words like “plan,” “expect,” “aim,” “believe,” “project,” “anticipate,” “commit,” “intend,” “estimate,” “will,” “should,” “could,” “potential” and other expressions that indicate future events and trends.

All statements that address expectations or projections about the future, including, without limitation, statements about product launches, governmental and regulatory actions and proceedings, market position, revenues, expenditures and the impact of the recall and suspension of shipments on revenues, adjustments to the financial statements, the filing of amended SEC filings and other financial results, are forward-looking statements.

All forward-looking statements are based on current expectations and are subject to risk and uncertainties. In connection with the PSLRA’s “safe harbor” provisions, we provide the following cautionary statements identifying important economic, competitive, political, regulatory and technological factors, among others, that could cause actual results or events to differ materially from those set forth or implied by the forward-looking statements and related assumptions. Such factors include (but are not limited to): (1) the ability of the Company and its subsidiaries to continue as a going concern; (2) the ability of the Company and its subsidiaries to obtain Bankruptcy Court approval with respect to motions in the Chapter 11 cases; (3) the ability of the Company and its subsidiaries to prosecute, develop and consummate one or more plans of reorganization with respect to the Chapter 11 cases; (4) the effects of the bankruptcy filing on the Company and its subsidiaries and the interests of various creditors, equity holders and other constituents; (5) the effects of rulings of the Bankruptcy Court in the Chapter 11 cases and the outcome of the cases in general; (6) the length of time the Company and its subsidiaries will operate under the Chapter 11 cases; (7) risks associated with third-party motions in the Chapter 11 cases, which may interfere with the ability of the Company and its subsidiaries to develop one or more plans of reorganization and consummate such plans once they are developed; (8) the potential adverse effects of the Chapter 11 proceedings on the Company’s liquidity or results of operations; (9) the ability to execute the Company’s business and restructuring plans; (10) increased legal costs related to the Company’s bankruptcy filing and other litigation; (11) the ability to continue listing of its Class A Common Stock and Class B Common Stock on the New York Stock Exchange; and (12) the ability of the Company and its subsidiaries to maintain contracts that are critical to their operation, including to obtain and maintain normal terms with their vendors, customers and service providers and to retain key executives, managers and employees.

This discussion is not exhaustive, but is designed to highlight important factors that may impact our forward-looking statements.

Because the factors referred to above, as well as the statements included in Part I, Item 1A—“Risk Factors,” of our Annual Report on Form 10-K for the fiscal year ended March 31, 2012 and under the heading “Risk Factors” in our Registration Statement on Form S-1 filed with the Securities and Exchange Commission on July 31, 2012, could cause actual results or outcomes to differ materially from those expressed in any forward-looking statements made by us or on our behalf, you should not place undue reliance on any forward-looking statements. All forward-looking statements attributable to us are expressly qualified in their entirety by the cautionary statements in this “Cautionary Note Regarding Forward-Looking Statements” and the risk factors that are included under Part I, Item 1A of the our Annual Report on Form 10-K for the fiscal year ended March 31, 2012 and under the heading “Risk Factors” in our Registration Statement on Form S-1 filed with the Securities and Exchange Commission on July 31, 2012. Further, any forward-looking statement speaks only as of the date on which it is made and we are under no obligation to update any of the forward-looking statements after the date of this release. New factors emerge from time to time, and it is not possible for us to predict which factors will arise, when they will arise and/or their effects. In addition, we cannot assess the impact of each factor on our future business or financial condition or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements.

EX-99.3 4 ex99-3.htm EXHIBIT 99.3 ex99-3.htm

Exhibit 99.3

Contact Information:

Brainerd Communicators, Inc.

Tony Herrling

212-739-6738

herrling@braincomm.com

Brad Edwards

212-739-6724

edwards@braincomm.com

K-V Pharmaceutical Class A and Class B Common Stock Begin Trading on the OTC Markets

St. Louis, MO, August 7, 2012 – K-V Pharmaceutical Company (“K-V” or “the Company”) today announced that its Class A and Class B common shares have begun trading on the OTCQB Marketplace.

The Company’s Class A and Class B common shares are trading on the OTCQB Marketplace under the symbols “KVPHA” and “KVPHB,” respectively.

The transition to the OTCQB Marketplace comes after the Company’s Class A and Class B common shares were suspended, pending delisting, from the NYSE as a result of the Company’s voluntary filing for protection under Chapter 11 of the U.S. Bankruptcy Code on August 4, 2012.

About K-V Pharmaceutical Company

For further information about K-V Pharmaceutical Company, please visit the Company’s corporate website at www.kvph.com.

Cautionary Note Regarding Forward-looking Statements

All forward-looking statements are based on current expectations and are subject to risk and uncertainties. In connection with the PSLRA’s “safe harbor” provisions, we provide the following cautionary statements identifying important economic, competitive, political, regulatory and technological factors, among others, that could cause actual results or events to differ materially from those set forth or implied by the forward-looking statements and related assumptions. Such factors include (but are not limited to): (1) the ability of the Company and its subsidiaries to continue as a going concern; (2) the ability of the Company and its subsidiaries to obtain Bankruptcy Court approval with respect to motions in the Chapter 11 cases; (3) the ability of the Company and its subsidiaries to prosecute, develop and consummate one or more plans of reorganization with respect to the Chapter 11 cases; (4) the effects of the bankruptcy filing on the Company and its subsidiaries and the interests of various creditors, equity holders and other constituents; (5) the effects of rulings of the Bankruptcy Court in the Chapter 11 cases and the outcome of the cases in general; (6) the length of time the Company and its subsidiaries will operate under the Chapter 11 cases; (7) risks associated with third-party motions in the Chapter 11 cases, which may interfere with the ability of the Company and its subsidiaries to develop one or more plans of reorganization and consummate such plans once they are developed; (8) the potential adverse effects of the Chapter 11 proceedings on the Company’s liquidity or results of operations; (9) the ability to execute the Company’s business and restructuring plans; (10) increased legal costs related to the Company’s bankruptcy filing and other litigation; (11) that its Class A Common Stock and Class B Common Stock will be, or will continue to be, traded on the OTCQB Marketplace and whether sufficient volumes and liquidity will develop; and (12) the ability of the Company and its subsidiaries to maintain contracts that are critical to their operation, including to obtain and maintain normal terms with their vendors, customers and service providers and to retain key executives, managers and employees.

This discussion is not exhaustive, but is designed to highlight important factors that may impact our forward-looking statements.

GRAPHIC 5 logo.jpg begin 644 logo.jpg M_]C_X``02D9)1@`!`@$`6@!:``#_X0HV17AI9@``34T`*@````@`!P$2``,` M```!``$```$:``4````!````8@$;``4````!````:@$H``,````!``(```$Q M``(````<````<@$R``(````4````CH=I``0````!````I````-``#;N@```G M$``-NZ```"<0061O8F4@4&AO=&]S:&]P($-3-"!7:6YD;W=S`#(P,3(Z,#@Z M,#<@,3(Z,S8Z-#8``````Z`!``,````!``$``*`"``0````!````>Z`#``0` M```!````40`````````&`0,``P````$`!@```1H`!0````$```$>`1L`!0`` M``$```$F`2@``P````$``@```@$`!`````$```$N`@(`!`````$```D````` M`````$@````!````2`````'_V/_@`!!*1DE&``$"``!(`$@``/_M``Q!9&]B M95]#30`!_^X`#D%D;V)E`&2``````?_;`(0`#`@("`D(#`D)#!$+"@L1%0\, M#`\5&!,3%1,3&!$,#`P,#`P1#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P, M#`$-"PL-#@T0#@X0%`X.#A04#@X.#A01#`P,#`P1$0P,#`P,#!$,#`P,#`P, M#`P,#`P,#`P,#`P,#`P,#`P,#`P,_\``$0@`40![`P$B``(1`0,1`?_=``0` M"/_$`3\```$%`0$!`0$!``````````,``0($!08'"`D*"P$``04!`0$!`0$` M`````````0`"`P0%!@<("0H+$``!!`$#`@0"!0<&"`4###,!``(1`P0A$C$% M05%A$R)Q@3(&%)&AL4(C)!52P6(S-'*"T4,')9)3\.'Q8W,U%J*R@R9$DU1D M1<*C=#87TE7B9?*SA,/3=>/S1B>4I(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F M]C='5V=WAY>GM\?7Y_<1``("`0($!`,$!08'!P8%-0$``A$#(3$2!$%187$B M$P4R@9$4H;%"(\%2T?`S)&+A7U5F9VAI:FML;6YO8G-T=7 M9W>'EZ>WQ__:``P#`0`"$0,1`#\`]4.FJ=)!IL][Z'?2K@CS8?H._P"^(7^* M0+!/9,DDDBA22222E))))*4DDDDI22222E))))*4DDDDI__0]/S;CCX=]XU- M5;W@?U6ER!E"ST:L['&^VENXL'-E;A-E?];_``E?_"*U=4VZE]+_`*-C2QWP M<-I5+HEKW8#:+?Y[%)Q[1YU^UO\`G5['*.6LN'I(:?WHLT*&/C`LPE4A^]CR M!N47U9%++Z7!]=@#FN'<%$61:\]'RC:?^3]?./9_5=5_TU:OHIR:G4WL#ZWB'-*C,>," M<3PS'\I0DS1F,4I8ICCQ2W'7^IFQ_P!?A9@AP#FF0=01P0J>7U.NAQKK'JVC MD#@?UG+*?7U+H0>RHOR>F.G:1[K*9[Q^N_=QGY.#]+^KD_$'_`,DCT]7,AN2S9/Y[>/FU`JLKN;NI:ZQO[S6N+?D^-J3ZVO:=#H8( M(((/PG49U_4KK`_ M2]K'D^DX_0#G3[MW[_[ZD^YR'")SB)2Z,?!1T-6=!;WU_5,>H%L['CDV`L8P M<;K'N#6?]+WH;K'F2XBS/+ MP7^Z-,H/Z!XF:`PC25PE^\1[D3_A1]$>'%\JN8A*9!@8RX1P^F4>+_`!/YS_F.@DJ;.K].<8-PK/A8'5G_ M`,%#%89D8]G\W:Q_]5P/Y%<$HG8@_5KRQSC\T91\Q21)))%8I))))3__T_54 MDDDE/C?4OJS]8']0R7LZ?D.:ZUY:X5N((+B000%W?U,Z/8SZLV=/ZKC.8+K+ M-]-H@EK@S6/I-X74I*QDYJ4XB-`40;'@OED)%/C7UB^K&;T;J@Q:VNNJO,XE MC1)S+Q2=U-K!N]I_,LV_X M1BV>C='^LW5Z\7I76F68_2<$[W;P6OM`_FJ)_/:S_P`#9_UI=]BLR64-;E6M MNN'TK&,],'_K>^W;_GHJ$N;F8T1$D;3Z_P!Y8-PH]4,#A"24T$&0``````!````!XX0DE-`_,```````D```````````$` M.$))32<0```````*``$``````````CA"24T#]0``````2``O9F8``0!L9F8` M!@```````0`O9F8``0"AF9H`!@```````0`R`````0!:````!@```````0`U M`````0`M````!@```````3A"24T#^```````<```____________________ M_________P/H`````/____________________________\#Z`````#_____ M________________________`^@`````____________________________ M_P/H```X0DE-!`@``````!`````!```"0````D``````.$))300>```````$ M`````#A"24T$&@`````#20````8``````````````%$```![````"@!5`&X` M=`!I`'0`;`!E`&0`+0`Q`````0`````````````````````````!```````` M``````![````40`````````````````````!```````````````````````` M`!`````!````````;G5L;`````(````&8F]U;F1S3V)J8P````$```````!2 M8W0Q````!`````!4;W`@;&]N9P``````````3&5F=&QO;F<``````````$)T M;VUL;VYG````40````!29VAT;&]N9P```'L````&7!E`````$YO M;F4````)=&]P3W5T/S1B>4I(6T ME<34Y/2EM<75Y?569G:&EJ:VQM;F]C='5V=WAY>GM\?7Y_<1``("`0($!`,$ M!08'!P8%-0$``A$#(3$2!$%187$B$P4R@9$4H;%"(\%2T?`S)&+A7U5F9VAI:FML;6YO8G-T=79W>'EZ>WQ__:``P#`0`"$0,1`#\`]4.F MJ=)!IL][Z'?2K@CS8?H._P"^(7^*0+!/9,DDDBA22222E))))*4DDDDI2222 M2E))))*4DDDDI__0]/S;CCX=]XU-5;W@?U6ER!E"ST:L['&^VENXL'-E;A-E M?];_``E?_"*U=4VZE]+_`*-C2QWP<-I5+HEKW8#:+?Y[%)Q[1YU^UO\`G5[' M*.6LN'I(:?WHLT*&/C`LPE4A^]CR!N47U9%++Z7!]=@#FN'<%$61:\]'RC:? M^3]?./9_ M5=5_TU:OHIR:G4WL#ZWB'-*C,>,"<3PS'\I0DS1F,4I8ICCQ2W'7^IFQ_P!? MA9@AP#FF0=01P0J>7U.NAQKK'JVCD#@?UG+*?7U+H0>RHOR>F.G:1[K*9[Q^ MN_=QGY.#]+^KD_$'_`,DCT]7,AN2S9/Y[>/FU`JLK MN;NI:ZQO[S6N+?D^-J3ZVO:=#H8((((/PG49U_4KK`_2]K'D^DX_0#G3[MW[_[ZD^YR'")SB)2Z M,?!1T-6=!;WU_5,>H%L['CDV`L8P<;K'N#6?]+WH;K'F2XBS/+P7^Z-,H/Z!XF:`PC25PE^\1[D3_A1]$>'%\JN8A*9!@8RX1P^F4>+_ M`!/YS_F.@DJ;.K].<8-PK/A8'5G_`,%#%89D8]G\W:Q_]5P/Y%<$HG8@_5KR MQSC\T91\Q21)))%8I))))3__T_54DDDE/C?4OJS]8']0R7LZ?D.:ZUY:X5N( M(+B000%W?U,Z/8SZLV=/ZKC.8+K+-]-H@EK@S6/I-X74I*QDYJ4XB-`40;'@ MOED)%/C7UB^K&;T;J@Q:VNNJO,XEC1)S+Q2=U-K!N]I_,LV_X1BV>C='^LW5Z\7I76F68_2<$[W;P6OM` M_FJ)_/:S_P`#9_UI=]BLR64-;E6MNN'TK&,],'_K>^W;_GHJ$N;F8T1$D;3Z M_P!Y8-PH]4,FMC.60B/SX@/'@Z>&UP;65T82!X;6QN#IX;7!T:STB061O8F4@6$U0($-O&UL;G,Z9&,](FAT='`Z+R]P=7)L+F]R9R]D8R]E;&5M96YT&UL;G,Z&%P+S$N M,"]S5'EP92]297-O=7)C945V96YT(R(@>&UL;G,Z<&AO=&]S:&]P/2)H='1P M.B\O;G,N861O8F4N8V]M+W!H;W1O&EF+S$N,"\B('AM<#I#&UP.DUE=&%D871A1&%T93TB M,C`Q,BTP."TP-U0Q,CHS-CHT-BTP-CHP,"(@>&UP.DUO9&EF>41A=&4](C(P M,3(M,#@M,#=4,3(Z,S8Z-#8M,#8Z,#`B(&1C.F9O&UP34TZ26YS=&%N8V5)1#TB>&UP+FEI9#HR,38Q,$5$13@W1$1%,3$Q M0D8S0D,X.34Q1C&UP34TZ1&]C=6UE;G1)1#TB>&UP+F1I9#HR M,38Q,$5$13@W1$1%,3$Q0D8S0D,X.34Q1C&UP34TZ3W)I9VEN M86Q$;V-U;65N=$E$/2)X;7`N9&ED.C(Q-C$P141%.#=$1$4Q,3%"1C-"0S@Y M-3%&-S8X1C$P(B!P:&]T;W-H;W`Z0V]L;W)-;V1E/2(S(B!P:&]T;W-H;W`Z M24-#4')O9FEL93TB&EF.DYA=&EV941I9V5S=#TB,S8X-C0L-#`Y-C`L-#`Y-C$L M,S&UP+FEI9#HR,38Q,$5$13@W1$1% M,3$Q0D8S0D,X.34Q1C&UP;65T M83X@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`\/WAP86-K970@96YD/2)W(C\^ M_^(,6$E#0U]04D]&24Q%``$!```,2$QI;F\"$```;6YT`",`*``M`#(`-P`[`$``10!*`$\`5`!9`%X`8P!H`&T`<@!W`'P`@0"& M`(L`D`"5`)H`GP"D`*D`K@"R`+<`O`#!`,8`RP#0`-4`VP#@`.4`ZP#P`/8` M^P$!`0&!YD'K`>_!]('Y0?X"`L('P@R"$8(6@AN"(((E@BJ M"+X(T@CG"/L)$`DE"3H)3PED"7D)CPFD";H)SPGE"?L*$0HG"CT*5`IJ"H$* MF`JN"L4*W`KS"PL+(@LY"U$+:0N`"Y@+L`O("^$+^0P2#"H,0PQ<#'4,C@RG M#,`,V0SS#0T-)@U`#5H-=`V.#:D-PPW>#?@.$PXN#DD.9`Y_#IL.M@[2#NX/ M"0\E#T$/7@]Z#Y8/LP_/#^P0"1`F$$,081!^$)L0N1#7$/41$Q$Q$4\1;1&, M$:H1R1'H$@<2)A)%$F02A!*C$L,2XQ,#$R,30Q-C$X,3I!/%$^44!A0G%$D4 M:A2+%*T4SA3P%1(5-!56%7@5FQ6]%>`6`Q8F%DD6;!:/%K(6UA;Z%QT701=E M%XD7KA?2%_<8&QA`&&48BABO&-48^AD@&449:QF1&;<9W1H$&BH:41IW&IX: MQ1KL&Q0;.QMC&XH;LAO:'`(<*AQ2''LP>%AY` M'FH>E!Z^'ND?$Q\^'VD?E!^_'^H@%2!!(&P@F"#$(/`A'"%((74AH2'.(?LB M)R)5(H(BKR+=(PHC."-F(Y0CPB/P)!\D321\)*LDVB4))3@E:"67)<`^(#Y@/J`^ MX#\A/V$_HC_B0"-`9$"F0.=!*4%J0:Q![D(P0G)"M4+W0SI#?4/`1`-$1T2* M1,Y%$D5519I%WD8B1F=&JT;P1S5'>T?`2`5(2TB12-=)'4EC2:E)\$HW2GU* MQ$L,2U-+FDOB3"I,%W)7AI>;%Z] M7P]?85^S8`5@5V"J8/QA3V&B8?5B26*<8O!C0V.78^MD0&249.EE/6629>=F M/6:29NAG/6>39^EH/VB6:.QI0VF::?%J2&J?:O=K3VNG:_]L5VRO;0AM8&VY M;A)N:V[$;QYO>&_1<"MPAG#@<3IQE7'P,QY*GF)>>=Z1GJE>P1[8WO"?"%\@7SA?4%]H7X! M?F)^PG\C?X1_Y8!'@*B!"H%K@%JX8.AG*& MUX<[AY^(!(AIB,Z),XF9B?Z*9(K*BS"+EHO\C&.,RHTQC9B-_XYFCLZ/-H^> MD`:0;I#6D3^1J)(1DGJ2XY--D[:4()2*E/257Y7)EC26GY<*EW67X)A,F+B9 M))F0F?R::)K5FT*;KYP0)ZNGQV?BY_ZH&F@V*%'H;:B)J*6 MHP:C=J/FI%:DQZ4XI:FF&J:+IOVG;J?@J%*HQ*DWJ:FJ'*J/JP*K=:OIK%RL MT*U$K;BN+:ZAKQ:OB[``L'6PZK%@L=:R2[+"LSBSKK0EM)RU$[6*M@&V>;;P MMVBWX+A9N-&Y2KG"NCNZM;LNNZ>$;R;O16]C[X*OH2^_[]ZO_7`<,#LP6?! MX$?PMO#6,/4Q%'$SL5+QHM\IWZ_@-N"]X43AS.)3XMOC8^/K MY'/D_.6$Y@WFENV<[BCNM.]`[\SP M6/#E\7+Q__*,\QGSI_0T],+U4/7>]FWV^_>*^!GXJ/DX^H6&AXB)BI25EI>8F9JDI::GJ*FJM+6VM[BYNL3%QL?( MR'EZ>WQ]?G]TA8:'B(F*BXR-CH^#E)66EY MB9FIN_=>Z][]U[KWOW7NO>_=>Z][ M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z__0W]R`000" M"+$'D$'Z@C\@^_=>!(-1QZ#O9>="9;<>P,A(5S&T7I*NB$I.O);,SC53[;RL M)95,J4KT=3C9F%R*F@=C8.MR/:KS3G".\@TBYB:G`L'CN4&/TYU`RK4$7V>=`[KWO MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z M][]U[KWOW7NO_]'>O[EWC4]=]0=K=@4<7GJ]B];;YWC2P^G]ZIVQMC*9N"+U M67]R6A`YXY]D/-6ZOL7*_,F]QK62SL+B<#U,43R`?M7H:>V_+D/.'N'R%RC< M/IM]UWJQLV/HMS@J]O8_2U7V M;UAG:"@KMZ[+IK,JSYJHHZ:'*X2]Q_&*""+B*HFN'>8A??NW:.<]AB:?<[*( M2&-?BNK215:>`>LA4+-!7_1XT7"NU1WR(^S?U@YH]IN=;A++E_=KEH$N)/@V MWUO:4_Q2>63+PQT'/8^]=L=C[0VYOO9>6IL[M;=>)I,U@\ MK2,3%54-9&)$UHP66GJ86O'-#(%E@F1HY%5U90+]HW;;]]VRQWC:KE9MNN8E MDC=>!5A7[01P930JP*D`@CJ+>9^6=\Y-YAWGE7F7;WM=]L+AX9XGXJZ&AH1A ME.&1U)5T*NI*L"55[,>B+KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7 MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[K__TM]3>6U\;O?:&ZMEYE/)B-W[;SFU M\K'8-KQN?QE5BJY+'@ZJ6K86/M#NFWP;MMFX[5="MK=021/_`*61"C?R)Z.> M7-\O.6.8=AYDVYJ;AM][!61H,P]6LDZI+44V;V@V-KH9K%9DJ0RLPY(!]I+^ZGY,L]FW M/&];/(^WW`]'MB$1L\1)#X4BG@0]17CU-'WFMEV^T]UMTYKV#NY3YIABWNQ> M@`:+<`99DH,*T-V+B!TXHT="`<=!3N;+R_"/M*KW35>MNP*U@]7$H\-!DF>1/&)%AJ`UN%TWM%S')N,@/^MGNU MQ66@J-MO9#F4`?#:7+9D`[8IB6%`VEA[LFWI]YSD6WV*#3_K_L1IH9 MK::6WN(FCN(V*LK`JRLIHRLIH0P((((J#@]9O=^FNO>_=>Z][]U[KWOW7NO> M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K_]/?X]^Z]T7;=.W1 MU?V7D.[\+"XVUN_$XS!=WXVFCUZ(=O1S1;3[3A@C4RRU>UJ.>3'Y?3=Y<,\4 MW/\`#D20#[C8_P!7M^GYNM5/T%S$D=^H%<1U$-V`,DPJ3'-3)@*M_H`!F#8M MX///)5I[8;E(#O6WW$D^RR,:5-P0;K;"Q-`MTZK/:5PMX'CQ]8S(,FX=O;5[ M#VIE-M[BQ^,W3L_=N'EH9P^3I[$"2)RLD,\,@>.6-@RG2Z,&"L! M3?6.W;YMMQ87\$=SM=S$5=31DD1Q\N((-00?0@UH>HYV?=]^Y/W^QWG9[R>P MYBV^X#QR+5)89HV]",%6!#*PHP-W?R\=^XOIWN#)97<_Q)W?D M7I.F>W*Y9ZZMZGJIBTD?7V^*B.-C_!*1;_;RVM%`OFB'VZSP4./&V[WN7L;O M-MRKS1<2W'ME=2:;"]:K-9$Y%K<,/]#'X&\E&I>P.L6.?>F\:8Z*VBIJG[;#X:4\>'*Y-(:DM7)]6 MIH4=TM:5HB5OCC[T?><]O_9Q)K2_N5NM]49A5PJQFG"5Z&C?T%!;^+345FCD M#V3WCFRSAWW>KP;;RX^4=EU2S#UBC)7L/E(Y`/%`X!H7>7Y'?(*KG-7346QZ M"FU:HZ'^`Y.==%[Z)IY<^9Y&T_E&CYYM^/>`&[?WHT-ON9BMK+;5MPWPD.V/ MFWB@_LIU,,?LS[1V\0MYKK=)9Z9?QXUSZA1!I`^1#?;Y]"9LWY;21UE/C.TM ML)@TGD2$;EV_]U4XN)WLIDKL14-4Y"DIE;ZO%-5/R/VP`6&3/L]]_;VZ]P[B MWV[?D2QN9"`)8V+Q5/\`&AJZ#Y@R?,`5/0)YD^[\K6TU[R+OANF12?II]*RD M#R25=,;M3R9(A_2)H.CFT5;1Y*CI\\;>X@NH(;FUF62VD4,K*0RLI%0RL*@@C((P1UC;Z8Z][]U[KWOW7NO>_=>Z][]U[ MKWOW7NO>_=>Z_]3?X]^Z]UPDC25'BD19(Y$:.1'`9'1P5=&4\,K*;$?D>],H M8%6%5(H>K([1LKHQ#J:@CB".!'16_BQFQA]M;BZ#S4QBWE\?,U+LF6DJ'45& M4ZZJ))\AU)N^DCN3)B\ULB2GI6<%@F1H*N$G5$1[CSV[N_I;"^Y,NFINNR2F M`J>+VI):SF4>:/!I2OE+'*G%>IT]]ML.X[UL_NQML>KESFZV%Z'4=L6X*%CW M6T<^4L-Z))0IH3;SV\@%)`>AYWWL/:'9NT\UL??F`Q^YMJ[@I'HLKA\G#Y:> M>)K,DL;J4FI:RFE`D@GB9)H)55XV5U!`QWG9MKY@VV[V?>;*.XVV==+QN*@C M_""#E6!#*0"""`>HIY6YJYBY)W_;>:.5=VFL=^M)`\4T9HRD<01E61A571PR M.I*NI4D=5/97;WR0_E_09_#;3J-V]R?$7+T^0AQ=7BZ9,[VI\?'KTD5,A18^ M0QPY?!8N27RD?MT,FC6QH)"S5&,NX;?[A>RUKN5CLMQ<[E[;S1R+%(J>->;4 MS@A9!&2/%BC)U::A#2I,+$E\^K'>/9G[V\NU;CO\.W\M_>$MWC,J2L8-KW\1 MD5C>05,,\H&FO=.M=*BZ0`0Y-G;BZ9H]HX3L%>T-H3[1W7%79##[ESV57;\^ M6%'5S4V2$U-N7^'9(9"AK(VCJHW36DP(]0L[?/M]\?DK[Q%KS+9W46QWN\X;>DMS#!J`0IU46X8L,,'D%LU_\GJ)3;\>X(Y1^X=]\7W`LOWOLGLUNGT; M"JOW,WCQ_P#- MR->NLQM['YJAKVCHZJ&2BJ9"^[%O.S3>YW)&Z['!%*\6AI$26-GC+J MKHVD-4HP8`J:];VW>+O;;NT5[E&61!)&\G ME;EI3[^B/^[U]_KCW!Y9/)N[79E>.'QK8L:E:4\2(5SI(/B*."D.?Q=!SWUY M7M-UV&R]P+"%5OXG2&ZI^-&[8I6\M2-2,DY99(UX1CH^GOICUBCU[W[KW7O? MNO=>]^Z]U[W[KW7O?NO=>]^Z]U__U=_CW[KW7O?NO=%B[[Z,W)O7)X+M7IS= M<'77?FQZ&?';>W)5T\E7MK>.V9ZE:^MZX[(QD-WR^T,C6)Y89%#5.+JF-136 M8NKQ]SGR??[M<6?,?*VYBPYSLT*Q2L-44\1.IK6Z09>!F%5([XG[X\U!F_VH M]T=FY9LMTY#]QM@;>?:?=)5DN+9&"7-G!*2*KK49`90:4/6)_,G+^X\ MJ;]NO+>[^#^]+*9HI1%+%/&'7X@LL+O$]#@E'8`@BM0>L.XMLX7(8>.CDVEM MS<%-CZI,A2X3*8O&STAF2O+*WDM?"& MWPRQJVH1LJE2:U.D$:0WF"<:N)''IW9][W.SW%[E.8+RTFEC,;312R*]"ND" M0H=;1@4#**G1\(-`I!+>_P`G=@;1IYL8*F;;V=I8X%R,W8&`W%LK9VR*2:>* MAARN\=TYK'8W;U+0O7314U%!3UKS96KFBAI24=IX@3S![C;/LMG=^''(-PAC M+%)HY((XZ87Q)9%2(:VTQQ*)"99&54-"663>6/9#FWF"6.],"WFU.6\,6$]O M>7EZX4N8K.UADDN&<(K23/)"$M8DDDG`95B=(Y#/Y2H^ZK MGP.(H:>>E=&>EGQ-70+)6S4,3Z7A\U96+8#U&Y/OYU?OI_?L]Z=VW'W!]C^? M?;+8CR9N5M)"$N]NN(;N)JGZ>\M;EIQ^K;N$EAE"21L12A1B"(+3:+&,06UC M:7%C]//4Q-/*[*X-&65)"$5R*J^B&(YX#AT`VP$>;Y#=:_9JY>/*9F63Q$^B MG7;.=,QDL>8_#J!O_7W+']U=!N?]<>76HWA!)BW^E\"2M?EPZECFUEC]H.=/ MJ6&DP0@5\V^I@I3YUIU:#[^ACK!KKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][] MU[K_UM_CW[KW29WAM:GWGMW)[U-I[7M=[+R78"6:VB MD:BM34\:N:=_"I-/EU,\&Q[-+!!*VUPZGC5C0&E2H)\_GUL2_P`MG^<-L'8/ M\NW=O;OS3[[S_9':NT>R=W4-/@:BCJL= M/TGV1NWI/`;MSF,V;UEU!U9DX<=(DF7R<6.PE-D]R?;4F5W#NG+UE5$LU7+) M##Y&TP14\7H$V[#[->WG*VR$;QMD-]/$ADFN;@,?A4ERJ`T2-0#10&:@JQ)Z M%%GRSLUA:_XS`LKJ"S.X/D,T'DH],G[3T<;YO==_SL/@S\>>L>_]_P#S8[CW M30;DF_A?:^"VGOK<5<.E=P9*9/[K8[.YR+(3T>=H7%I#M42LHJA*_&!QH/(CB!Q(SY$=!U_+%_G2]C8OMV7I7^8%V)D>[_ M`(W]SI2[5RF:[6%)ND=:YVIJ2F,W#D*O*4TU16[)K)IA!EH*AY(Z.(1UL.@T MTL=0W[P^PG*_,_*UY_5WENU6^B1B]L$K%=14JT9C;4OB"FJ,@=Q!0Y*D&TMC M?;)&*_L]3'-+:\201@9+&-XM M(!-0!42IM/WKN9]_>SVSW5]OMCYP8:46>>$V>Y@+@*NX6?AN`!Q+QN<:F)H: MU_\`\O*L^9G>*8OYRX7K[+Y;:M37[OP6R-C[\[CW!URG:VW)(GQ"[_IMEU5# MOG:>(QTLIE6C6.HH*?[N%WCCG@6&>03M[#;C]V.YDY/Y%]O_`&WW.XCA0276 MW6,NT;A#P+6YEK-;LQ`&LZ>%`2I)`.^9N8ONY,I;;S M8QN*D#6'MKY@I(P=1X5SCJXFD^46\\-I@[1^*?R%V54*+U%=M/![?[EVY$`S M*SKD>M<[E\V\8MJ!.,0Z3X6ZVM$YA]N=[M'\VACCOHA\]5K(\E/^ M;0_+J,+CV,Y;W*LO(WOURAN<1^%+J>?9[@^@,>Y00P@^6+DYP">/2PQ?RW^/ M.2G6DJ>R*':M]FOP&L=WM9A_PN5'_X MZQZCS/7O? MNO=>]^Z]U[W[KW7_U]_CW[KW7O?NO=?-8^1W\M/Y_9KY!=X9K#_#_P"0.6Q& M8[:[#RV*RF*ZRW1E,;D<;DMV9:MH:VAR./Q]315E+54LZ.DD4CHRM<$^^CVQ M>XW(,>Q;)%+SEMR2I90*RM,H966)`P(-"""""#U-=IO6T"TM5;+F%9CI)*.HM!54]13I/"598Y/>*_O)S=;R^Y=IS'RCO:2O;6U MOHFA;4%D342`>!I6C#*D$@U!(Z`',NXHV^17NW708I&E&4U`(K_J/EUJ7_S$ MOY8_[[<4M4K?W=K(L;3Z$WSM M(S1PY*&)4#*8ZQ$C@J(U7*;D/W-V/F_E2YY@O;NWLYK*(F^$CJD<`526F+.0 MJV[@%@S&BY1C49D/8MVCWNVC:)/\];UYN[NNMVCD=D)ML[OP^_T>U:O+PX;? MFT\;!HKJB2K2JG2-*W4M5%52+A9SANO*IYD7G7V@NMPN.71.'^KAL;U+&"XU MX$%X\"V\L+ME"CM&,I4KIJBYV]KN:^3C^_KFP2PB!#^#-<6T=U&3D'Z5IOJ5 M4^2M$&%=)6E.M<7YK_R/?F'T1W]NW:O0_3?8_>O3-=529WK;?&S,)-N"HCVY M7S2/3;?W;'C$+8W=>WF!I:@M'%'6"-:J%5CE\<>7G)GO3RAOVPV=[OF]VNW[ MTHTS12,4&L<7CJ*&-_B%#5#53P!/MLYGVV[M(Y;JZCANAAE8TSZK\CQ^7#JR MKX;?#_\`F9?-';?1/Q#^=>V^P.J/A)\:,DN[,Y#NO%9+:F]^X:3&20+L3J>L MR%37#([@PVW5,T%+/'##%BL6T@,K5<.,\4>$0\5L6'ZMP!0!'?!(J=;\`$,E2;KI9&JWJHL?3C'F%WB!9H<8DL;#<(K6]ON8E7O?Q;[ M>B,>"^*JOGAU95[^I4H<7G]O[5:]*V+>>ZJ*;"4-1\?:ZBEK>K:5L5L_)9>HI,#GJA\*)IZ.FHUJHC)63T2<>U*E3MKN7.3;@.%RG26_-GXN7MC/==T>R/HNZ_]#?X]^Z]U[W M[KW7O?NO=>]^Z]T6+Y"FW-L_.U^ M,J<;39O%UC*E5XHX:J2*KI(YX(\A1RR4\K!'N%>W3V]KN6VW5_81WNUPW$([A)DGV<.LE=59:ZJ\2 M3X=23QJ(( MXM0].P$#!).2!9VA>5VMXF2(\%+:B/\`;:5K^SI>^T'377O?NO=>]^Z]U[W[ MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U__]'?X]^Z]U[W[KW7O?NO=>]^Z]U[ MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO (=>]^Z]U__]D_ ` end